Metabolic syndrome in pediatrics: old concepts revised, new concepts discussed

Ebe D'Adamo1, Nicola Santoro, Sonia Caprio

  • 1Department of Pediatrics, Yale University School of Medicine, PO Box 208064, New Haven, CT 6520, USA.

Insights

Childhood obesity is driving an epidemic of metabolic syndrome in children. This article explores the causes of metabolic syndrome and highlights obesity's critical role in pediatric cases.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Public Health

Background:

  • Childhood obesity has reached epidemic proportions globally.
  • Metabolic syndrome, previously an adult disorder, is increasingly diagnosed in children.
  • Insulin resistance is a primary factor in metabolic syndrome development.

Purpose of the Study:

  • To examine the causes of metabolic syndrome in children.
  • To emphasize the significant role of obesity in pediatric metabolic syndrome.
  • To discuss the rising prevalence of metabolic syndrome in pediatric populations.

Main Methods:

  • Literature review on childhood obesity and metabolic syndrome.
  • Analysis of etiological factors contributing to pediatric metabolic syndrome.
  • Epidemiological data review on obesity and metabolic syndrome prevalence.

Main Results:

  • Childhood obesity is a major driver for the increased incidence of metabolic syndrome in pediatric patients.
  • Insulin resistance, particularly in carbohydrate metabolism, is central to metabolic syndrome pathogenesis.
  • The prevalence of metabolic syndrome is directly influenced by the prevalence of childhood obesity.

Conclusions:

  • Obesity is a critical factor in the rising rates of metabolic syndrome among children.
  • Understanding the causes of pediatric metabolic syndrome is essential for public health interventions.
  • Early identification and management of childhood obesity are crucial to prevent metabolic syndrome.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...